Keyphrases
Type 2 Diabetes Mellitus (T2DM)
100%
Meta-analysis
100%
Type 2 Diabetes Prevention
100%
Interleukin-1β
100%
Anti-interleukin-1
40%
Phase II Study
40%
Low-grade Inflammation
40%
Hemoglobin A1c (HbA1c)
40%
Cardiovascular Endpoints
20%
Diabetic
20%
Drug Candidates
20%
Protein-peptide Complexes
20%
Pathogenic Process
20%
Type 2 Diabetes Risk
20%
Clinical Trials
20%
C-reactive Protein
20%
Weight Loss
20%
Phenotypic Heterogeneity
20%
Obesity
20%
Anti-inflammatory Drugs
20%
Regression Analysis
20%
Insulin Resistance
20%
β-cell Dysfunction
20%
Antidiabetic Treatment
20%
Effective Means
20%
C-peptide
20%
Nave
20%
Inflammatory Cytokines
20%
Diabetes Subtypes
20%
Pharmacological Therapy
20%
Antagonism
20%
Medicine and Dentistry
Maturity Onset Diabetes of the Young
100%
Meta-Analysis
100%
Interleukin 1
100%
Hemoglobin A1c
28%
Biological Marker
28%
Drug Therapy
14%
Biological Product
14%
C Reactive Protein
14%
Inflammatory Cytokine
14%
Cardiovascular System
14%
Insulin Resistance
14%
C-Peptide
14%
Anti-Inflammatory Drug
14%
Diabetic Treatment
14%
Clinical Trial
14%
Prevalence
14%
Beta Cell
14%
Meta-Regression
14%
Antidiabetic Agent
14%
Pharmacology, Toxicology and Pharmaceutical Science
Interleukin 1
100%
Non Insulin Dependent Diabetes Mellitus
100%
Hemoglobin A1c
28%
Inflammation
28%
Biological Marker
28%
Antidiabetic Agent
14%
C Reactive Protein
14%
Biological Product
14%
Anti-Inflammatory Drug
14%
Syndrome
14%
Clinical Trial
14%
Insulin Resistance
14%
Prevalence
14%
C Peptide
14%
Cytokine
14%
Pharmacotherapy
14%